Clinical Trials Logo

Antisocial Behavior clinical trials

View clinical trials related to Antisocial Behavior.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03627312 Completed - Antisocial Behavior Clinical Trials

Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders

Start date: March 1, 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The study aims to examine the effects of providing omega-3 supplements on young offenders' antisocial behaviour. Participants will be randomized into three groups: (1) Omega-3, (2) Placebo and (3) Treatment as Usual. Self report and correctional officer ratings of behaviour will be assessed at 0 months (baseline), 3 months (end of supplementation), 6 months and 12 months. The investigators hypothesize that omega-3 supplementation will reduce antisocial behaviour among the young offenders.

NCT ID: NCT03036683 Completed - Aggression Clinical Trials

Transcranial Direct Current Stimulation in Offenders

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This study investigates the effect of upregulating prefrontal cortex activity on risk-taking, and antisocial and aggressive behavior in violent offenders. In the double-blind, randomized controlled trial, using a within-subject crossover design, each participant will undergo anodal transcranial direct current stimulation of the right dorsolateral prefrontal cortex and sham stimulation. After each stimulation session, neural activity and behavioral responses to tasks assessing risk-taking and aggressive behavior will be recorded. The effect of tDCS on violent offenders will also be assessed in comparison to age and gender-matched healthy controls.

NCT ID: NCT03035877 Completed - Antisocial Behavior Clinical Trials

Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse

Start date: August 28, 2017
Phase: N/A
Study type: Interventional

This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. The study will also examine that effect on intermediate outcomes as follows: 1) reduced AOD use; 2) greater gainful activity (increased educational success, employment and housing stability; decreased antisocial peer involvement and relationship conflict); 3) and greater improvement in self-regulation (self-efficacy, goal directedness and responsibility taking). The intervention to be tested is Multisystemic Therapy-Emerging Adults (MST-EA). MST-EA is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.

NCT ID: NCT02922335 Completed - Antisocial Behavior Clinical Trials

Multisystemic Therapy-Emerging Adults Trial

MST-EA
Start date: September 1, 2016
Phase: N/A
Study type: Interventional

This study's purpose is to test the effectiveness of a promising intervention for emerging adults (EAs) with mental illness (MI) and serious antisocial behavior in achieving the ultimate outcome of reduced antisocial behavior, and proximal intermediate outcomes. Multisystemic Therapy-Emerging Adults (MST-EA) is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.

NCT ID: NCT02674516 Completed - Aggression Clinical Trials

The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior

Start date: January 2016
Phase: N/A
Study type: Interventional

This study investigates the relationship between prefrontal cortex activity and antisocial and aggressive behavior, and risk factors for such behavior. In the double-blind, randomized controlled trial, participants will undergo three sessions of anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex or sham stimulation and complete survey and laboratory measures assessing antisocial behavior and risk factors. Heart rate and skin conductance will also be measured.

NCT ID: NCT02427672 Completed - Aggression Clinical Trials

The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior

Start date: March 2015
Phase: N/A
Study type: Interventional

This study investigates the effect of upregulating prefrontal cortex activity on antisocial and aggressive behavior and risk factors for such behavior. In the double-blind, randomized controlled trial, participants will undergo anodal transcranial direct current stimulation bilaterally to the dorsolateral prefrontal cortex or a sham stimulation. During and after stimulation, they will complete survey and laboratory measures assessing antisocial and aggressive behavior and risk factors for antisocial and aggressive behavior. Heart rate and skin conductance will also be measured.

NCT ID: NCT02334098 Completed - Aggression Clinical Trials

Omega-3 Supplementation and Behavior Problems

Start date: February 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The objectives of this project are as follows: 1. To assess whether omega-3 dietary supplementation for six months can reduce externalizing behavior problems (antisocial and aggressive behavior) in schoolchildren aged 8 to 18, both at the end of treatment and six months post-treatment 2. To assess whether omega-3 supplementation is more effective in children with more psychopathic-like traits.

NCT ID: NCT00708695 Completed - HIV Infections Clinical Trials

Age-17 Follow-up of Home Visiting Intervention

MemphisY17
Start date: May 2008
Phase:
Study type: Observational

This study is a longitudinal follow-up of 670 primarily African-American women and their 17-year-old firstborn children enrolled since 1990 in a highly significant randomized controlled trial (RCT) of prenatal and infancy home visiting by nurses. Nurses in this program are charged with improving pregnancy outcomes, child health and development, and maternal economic self-sufficiency. This follow-up examines whether earlier program effects on maternal and child functioning lead to less violent antisocial behavior, psychopathology, substance use and use-disorders, and risk for HIV; whether these effects are greater for those at both genetic and environmental risk; and whether program effects replicate those found with whites in an earlier trial.